Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Notice of Meeting, 75572-75573 [2014-29570]
Download as PDF
<![CDATA[
75572
Federal Register / Vol. 79, No. 243 / Thursday, December 18, 2014 / Notices
establish legally enforceable
responsibilities. See 21 CFR 10.115(d).
II. Paperwork Reduction Act of 1995
This guidance contains no collection
of information. As discussed in the
guidance, FDA intends to develop
individual guidances to specify the
electronic formats for certain
submissions under section 745A(a) of
the FD&C Act. We will discuss any
information collection subject to
clearance by OMB under the Paperwork
Reduction Act in each Federal Register
notice announcing the availability of the
individual guidances that specify the
required electronic formats.
III. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
IV. Electronic Access
Persons with access to the Internet
may obtain the document at https://www.
fda.gov/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/
default.htm,
https://www.fda.gov/BiologicsBlood
Vaccines/GuidanceCompliance
RegulatoryInformation/Guidances/
default.htm, or https://
www.regulations.gov.
Dated: December 12, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014–29609 Filed 12–17–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Center for Complementary &
Alternative Medicine; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council for
Complementary and Alternative
Medicine.
The meeting will be open to the
public as indicated below, with
VerDate Sep<11>2014
19:23 Dec 17, 2014
Jkt 235001
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Complementary and Alternative
Medicine
Date: February 6, 2015.
Closed: 8:30 a.m. to 9:45 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Open: 10:00 a.m. to 4:00 p.m.
Agenda: Report from the Institute Director
and other staff.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Martin H. Goldrosen,
Ph.D., Director, Division of Extramural
Activities, National Center for
Complementary and Alternative Medicine,
NIH, 6707 Democracy Blvd., Ste. 401,
Bethesda, MD 20892–5475, (301) 594–2014,
goldrosm@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
nccam.nih.gov/about/naccam/, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Dated: December 12, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–29571 Filed 12–17–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development (NICHD); Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Child Health and
Human Development Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available. A
portion of this meeting will be closed to
the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review and
discussion of grant applications.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
Name of Committee: National Advisory
Child Health and Human Development
Council.
Date: January 22, 2015.
Open: January 22, 2015, 8:00 a.m. to 12:10
p.m.
Agenda: Report of the Director, NICHD;
Report of the Acting Director, Division of
Extramural Research, NICHD; Discussion of
the Outstanding Investigator Award (R35);
and New Business of the Council.
Closed: January 22, 2015, 1:15 p.m. to
Adjournment.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Center Drive, C-Wing,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Caroline Signore, MD.,
Mp.H., Acting Director, Division of
Extramural Research, Eunice Kenney Shriver
National Institute of Child Health and
Human Development, NIH, 6100 Executive
Blvd., Room 4A05, MSC 7510, Bethesda, MD
20892, (301) 496–5577.
Any interested person may file written
comments with the committee by forwarding
the statement to the contact person listed on
this notice. The statement should include the
name, address, telephone number, and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
E:\FR\FM\18DEN1.SGM
18DEN1
Federal Register / Vol. 79, No. 243 / Thursday, December 18, 2014 / Notices
onto the NIH campus. All visitor vehicles,
including taxis, hotel, and airport shuttles,
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
In order to facilitate public attendance at
the open session of Council in the main
meeting room, Conference Room 6, please
contact Ms. Lisa Kaeser, Program and Public
Liaison Office, NICHD, at 301–496–0536 to
make your reservation, additional seating
will be available in the meeting overflow
rooms, Conference Rooms 7 and 8.
Individuals will also be able to view the
meeting via NIH Videocast. Please go to the
following link for Videocast access
instructions at: https://www.nichd.nih.gov/
about/advisory/nachhd/Pages/virtualmeeting.aspx.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment program, National
Institutes of Health, HHS)
Dated: December 12, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–29570 Filed 12–17–14; 8:45 am]
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Advisory Committee to the Deputy
Director for Intramural Research,
National Institutes of Health.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Advisory Committee
to the Deputy Director for Intramural
Research, National Institutes of Health.
Date: January 9, 2015.
Time: 1:30 p.m. to 3:00 p.m.
Agenda: To discuss the Advisory
Committee to the Deputy Director for
Intramural Research Report
recommendations on the site visit review of
the Office of Animal Care and Use.
Place: National Institutes of Health,
Building 1, Room 160, Tele: 866–556–1098,
Jkt 235001
[FR Doc. 2014–29573 Filed 12–17–14; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
19:23 Dec 17, 2014
Dated: December 12, 2014.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
VerDate Sep<11>2014
Code 48960, 8600 Rockville Pike, Bethesda,
MD 20892, (Telephone Conference Call).
Contact Person: Michael M. Gottesman,
Deputy Director, National Institutes of
Health, Building One, Room 160, Bethesda,
MD 20892, 301–496–1921.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Prospective Grant of Exclusive
License: Multivalent Vaccines for
Rabies Virus and Ebola and Marburg
(Filoviruses)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR 404, that
the National Institutes of Health (NIH),
Department of Health and Human
Services (HHS), is contemplating the
grant of a an exclusive license to
practice the following invention as
embodied in the following patent
applications: E–032–2011/0, Blaney et
al., ‘‘Multivalent Vaccines for Rabies
Virus and Filoviruses’’, U.S. Patent
Application Number 61/439,046, filed
on February 3, 2011, PCT Application
Number PCT/US2012/23575, filed on
February 2, 2012, U.S. Patent
Application Number 13/983,545, filed
on August 2, 2013, European Patent
Application Number 12702953.6, filed
on February 2, 2012, and Canadian
Patent Application Number 2826594,
filed on February 2, 2012, to Exxell BIO,
Inc., having a place of business in
Shoreview, Minnesota, United States of
America. The patent rights in these
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
75573
inventions have been assigned to the
United States of America and Thomas
Jefferson University.
DATES: Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before
January 20, 2015 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Peter Soukas, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Email:
ps193c@nih.gov; Telephone: (301) 435–
4646; Facsimile: (301) 402–0220.
SUPPLEMENTARY INFORMATION: The
inventors have developed a new
platform based on live or chemically
inactivated (killed) rabies virus (RABV)
virions containing EBOV glycoprotein
(GP) in their envelope. In preclinical
trials, immunization with such
recombinant RABV virions provided
excellent protection in mice against
lethal challenge with the mouse adapted
EBOV and RABV. More specifically, the
inventors have developed a trivalent
filovirus vaccine based on killed rabies
virus virions for use in humans to
confer protection from all medically
relevant filoviruses and RABV. Two
additional vectors containing EBOV
Sudan GP or MARV GP are planned to
be constructed in addition to the
previously developed EBOV Zaire GP
containing vaccine. Live attenuated
vaccines have been developed for use in
at risk nonhuman primate populations
in Africa and inactivated vaccines have
been developed for use in humans. One
recent use contemplated by the
inventors is use of the vaccine
candidates to generate polyclonal sera
against Filoviruses (i.e. Ebola and
Marburg).
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.
These patent rights are the subject of
a previous Federal Register notice (see
79 FR 18039, Monday, March 31, 2014).
The fields of use may be limited to
production of polyclonal antibodies for
prevention/treatment of Filoviruses in
humans and non-human animals.
E:\FR\FM\18DEN1.SGM
18DEN1
]]>Agencies
[Federal Register Volume 79, Number 243 (Thursday, December 18, 2014)]
[Notices]
[Pages 75572-75573]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-29570]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development (NICHD); Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory Child Health and Human Development Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. A portion of this meeting will
be closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the
review and discussion of grant applications. Individuals who plan to
attend and need special assistance, such as sign language
interpretation or other reasonable accommodations, should notify the
contact person listed below in advance of the meeting.
Name of Committee: National Advisory Child Health and Human
Development Council.
Date: January 22, 2015.
Open: January 22, 2015, 8:00 a.m. to 12:10 p.m.
Agenda: Report of the Director, NICHD; Report of the Acting
Director, Division of Extramural Research, NICHD; Discussion of the
Outstanding Investigator Award (R35); and New Business of the
Council.
Closed: January 22, 2015, 1:15 p.m. to Adjournment.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, Center Drive,
C-Wing, Conference Room 6, Bethesda, MD 20892.
Contact Person: Caroline Signore, MD., Mp.H., Acting Director,
Division of Extramural Research, Eunice Kenney Shriver National
Institute of Child Health and Human Development, NIH, 6100 Executive
Blvd., Room 4A05, MSC 7510, Bethesda, MD 20892, (301) 496-5577.
Any interested person may file written comments with the
committee by forwarding the statement to the contact person listed
on this notice. The statement should include the name, address,
telephone number, and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance
[[Page 75573]]
onto the NIH campus. All visitor vehicles, including taxis, hotel,
and airport shuttles, will be inspected before being allowed on
campus. Visitors will be asked to show one form of identification
(for example, a government-issued photo ID, driver's license, or
passport) and to state the purpose of their visit.
In order to facilitate public attendance at the open session of
Council in the main meeting room, Conference Room 6, please contact
Ms. Lisa Kaeser, Program and Public Liaison Office, NICHD, at 301-
496-0536 to make your reservation, additional seating will be
available in the meeting overflow rooms, Conference Rooms 7 and 8.
Individuals will also be able to view the meeting via NIH Videocast.
Please go to the following link for Videocast access instructions
at: https://www.nichd.nih.gov/about/advisory/nachhd/Pages/virtual-meeting.aspx.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment program, National
Institutes of Health, HHS)
Dated: December 12, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-29570 Filed 12-17-14; 8:45 am]
BILLING CODE 4140-01-P
